These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 29776954)
1. Role of Elevated Bezrookove V; Nosrati M; Miller JR; De Semir D; Dar AA; Vosoughi E; Vaquero E; Sucker A; Lazar AJ; Gershenwald JE; Davies MA; Schadendorf D; Kashani-Sabet M Clin Cancer Res; 2018 Sep; 24(17):4119-4125. PubMed ID: 29776954 [No Abstract] [Full Text] [Related]
2. Prognostic impact of PHIP copy number in melanoma: linkage to ulceration. Bezrookove V; De Semir D; Nosrati M; Tong S; Wu C; Thummala S; Dar AA; Leong SPL; Cleaver JE; Sagebiel RW; Miller JR; Kashani-Sabet M J Invest Dermatol; 2014 Mar; 134(3):783-790. PubMed ID: 24005052 [TBL] [Abstract][Full Text] [Related]
3. Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasis. De Semir D; Nosrati M; Bezrookove V; Dar AA; Federman S; Bienvenu G; Venna S; Rangel J; Climent J; Meyer Tamgüney TM; Thummala S; Tong S; Leong SP; Haqq C; Billings P; Miller JR; Sagebiel RW; Debs R; Kashani-Sabet M Proc Natl Acad Sci U S A; 2012 May; 109(18):7067-72. PubMed ID: 22511720 [TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of primary cutaneous melanoma and clinical outcome. Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A; J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Jönsson G; Busch C; Knappskog S; Geisler J; Miletic H; Ringnér M; Lillehaug JR; Borg A; Lønning PE Clin Cancer Res; 2010 Jul; 16(13):3356-67. PubMed ID: 20460471 [TBL] [Abstract][Full Text] [Related]
6. Identification of subgroups along the glycolysis-cholesterol synthesis axis and the development of an associated prognostic risk model. Zhang E; Chen Y; Bao S; Hou X; Hu J; Mu OYN; Song Y; Shan L Hum Genomics; 2021 Aug; 15(1):53. PubMed ID: 34384498 [TBL] [Abstract][Full Text] [Related]
7. MiRNAs as Potential Prognostic Biomarkers for Metastasis in Thin and Thick Primary Cutaneous Melanomas. Valentini V; Zelli V; Gaggiano E; Silvestri V; Rizzolo P; Bucalo A; Calvieri S; Grassi S; Frascione P; Donati P; Soda G; Ottini L; Richetta AG Anticancer Res; 2019 Aug; 39(8):4085-4093. PubMed ID: 31366492 [TBL] [Abstract][Full Text] [Related]
8. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264 [TBL] [Abstract][Full Text] [Related]
9. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival. Roh MR; Gupta S; Park KH; Chung KY; Lauss M; Flaherty KT; Jönsson G; Rha SY; Tsao H J Invest Dermatol; 2016 May; 136(5):1002-1011. PubMed ID: 26854490 [TBL] [Abstract][Full Text] [Related]
10. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454 [TBL] [Abstract][Full Text] [Related]
11. PUMA expression is significantly reduced in human cutaneous melanomas. Karst AM; Dai DL; Martinka M; Li G Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057 [TBL] [Abstract][Full Text] [Related]
12. Glypican 6 is a putative biomarker for metastatic progression of cutaneous melanoma. Li Y; Li M; Shats I; Krahn JM; Flake GP; Umbach DM; Li X; Li L PLoS One; 2019; 14(6):e0218067. PubMed ID: 31199813 [TBL] [Abstract][Full Text] [Related]
13. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. Gerami P; Jewell SS; Pouryazdanparast P; Wayne JD; Haghighat Z; Busam KJ; Rademaker A; Morrison L J Mol Diagn; 2011 May; 13(3):352-8. PubMed ID: 21497295 [TBL] [Abstract][Full Text] [Related]
14. PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer. de Semir D; Bezrookove V; Nosrati M; Dar AA; Wu C; Shen J; Rieken C; Venkatasubramanian M; Miller JR; Desprez PY; McAllister S; Soroceanu L; Debs RJ; Salomonis N; Schadendorf D; Cleaver JE; Kashani-Sabet M Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5766-E5775. PubMed ID: 29866840 [TBL] [Abstract][Full Text] [Related]
15. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation]. Lázár V Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354 [TBL] [Abstract][Full Text] [Related]
16. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Scala S; Ottaiano A; Ascierto PA; Cavalli M; Simeone E; Giuliano P; Napolitano M; Franco R; Botti G; Castello G Clin Cancer Res; 2005 Mar; 11(5):1835-41. PubMed ID: 15756007 [TBL] [Abstract][Full Text] [Related]
17. PTEN expression in melanoma: relationship with patient survival, Bcl-2 expression, and proliferation. Mikhail M; Velazquez E; Shapiro R; Berman R; Pavlick A; Sorhaindo L; Spira J; Mir C; Panageas KS; Polsky D; Osman I Clin Cancer Res; 2005 Jul; 11(14):5153-7. PubMed ID: 16033830 [TBL] [Abstract][Full Text] [Related]
18. Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers? Branca M; Orso S; Molinari RC; Xu H; Guerrier S; Zhang Y; Mili N Melanoma Res; 2018 Feb; 28(1):21-29. PubMed ID: 29194095 [TBL] [Abstract][Full Text] [Related]
19. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Gerami P; Cook RW; Wilkinson J; Russell MC; Dhillon N; Amaria RN; Gonzalez R; Lyle S; Johnson CE; Oelschlager KM; Jackson GL; Greisinger AJ; Maetzold D; Delman KA; Lawson DH; Stone JF Clin Cancer Res; 2015 Jan; 21(1):175-83. PubMed ID: 25564571 [TBL] [Abstract][Full Text] [Related]
20. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Rákosy Z; Vízkeleti L; Ecsedi S; Vokó Z; Bégány A; Barok M; Krekk Z; Gallai M; Szentirmay Z; Adány R; Balázs M Int J Cancer; 2007 Oct; 121(8):1729-37. PubMed ID: 17594688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]